Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ArkBio and Scripps Research Extend Partnership for Novel Respiratory Candidate

publication date: Mar 17, 2023

Shanghai Ark Biopharma renewed its co-development collaboration with Calibr, a division of San Diego’s Scripps Research, to develop AK0705, a potential first-in-class drug targeting an enzyme involved in respiratory inflammation. ArkBio will lead the preclinical development of the enzyme, with Calibr contributing its expertise. AK0705 is being developed to treat a broad spectrum of respiratory diseases, including chronic obstructive pulmonary disease. Ark, which specializes in pediatric and respiratory diseases, expects to start clinical studies of AK0705 in 2024. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China